

## Exhibit I - Unaudited Interim Financial Information

### Deep Isolation Nuclear, Inc. and Subsidiaries Condensed Consolidated Balance Sheets (in thousands, except share and per share data)

	March 31, 2026 (Unaudited)	December 31, 2025
<b>Assets</b>		
<b>Current assets:</b>		
Cash	\$ 22,226	\$ 27,434
Accounts receivable, net of allowance for credit losses of \$120 thousand and \$118 thousand, respectively	593	439
Contract assets	614	275
Other current assets	622	672
<b>Total current assets</b>	<b>24,055</b>	<b>28,820</b>
Property, plant and equipment, net	142	128
Intangible assets, net	53	73
Finance lease right-of-use assets	10	11
Operating lease right-of-use assets	240	269
Goodwill	182	182
Other non-current assets	\$ 86	\$ 140
<b>Total assets</b>	<b>\$ 24,768</b>	<b>\$ 29,623</b>
<b>Liabilities and Stockholders' Equity</b>		
<b>Current liabilities:</b>		
Accounts payable	\$ 1,239	\$ 1,113
Accrued payroll	329	774
Contract liabilities	75	150
Finance lease liabilities, current	3	3
Operating lease liabilities, current	129	125
Other current liabilities	513	101
<b>Total current liabilities</b>	<b>2,288</b>	<b>2,266</b>
Finance lease liabilities, net of current portion	8	9
Operating lease liabilities, net of current portion	118	152
<b>Total liabilities</b>	<b>2,414</b>	<b>2,427</b>
Commitments and Contingencies (Note 16)		
<b>Stockholders' Equity</b>		
Common stock, par value \$0.0001 per share, 300,000,000 shares authorized, 57,647,613 and 57,542,113 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	6	6
Additional paid-in capital	59,982	59,456
Accumulated deficit	(37,919)	(32,503)
Accumulated other comprehensive income	285	237
<b>Total stockholders' equity</b>	<b>22,354</b>	<b>27,196</b>
<b>Total liabilities and stockholders' equity</b>	<b>\$ 24,768</b>	<b>\$ 29,623</b>

**Deep Isolation Nuclear, Inc. and Subsidiaries**  
**Condensed Consolidated Statements of Operations and Comprehensive Loss**  
(Unaudited) (in thousands, except share and per share data)

	Three Months Ended March 31,	
	2026	2025
Revenue	\$ 1,447	\$ 1,520
Cost of services (exclusive of depreciation shown separately below)	(681)	(662)
<b>Gross profit</b>	<b>766</b>	<b>858</b>
<b>Operating expenses:</b>		
Depreciation and amortization expense	25	29
Research and development expense	3,489	-
Selling, general and administrative expenses	2,840	993
Total operating expenses	6,354	1,022
<b>Loss from operations</b>	<b>(5,588)</b>	<b>(164)</b>
Other income (expense)	172	(1)
<b>Net loss before income taxes</b>	<b>(5,416)</b>	<b>(165)</b>
Provision for income taxes	-	1
<b>Net loss</b>	<b>\$ (5,416)</b>	<b>\$ (166)</b>
<b>Other comprehensive loss:</b>		
Foreign currency translation adjustments	48	(49)
Total other comprehensive income (loss)	48	(49)
<b>Other comprehensive loss</b>	<b>\$ (5,368)</b>	<b>\$ (215)</b>
Net loss per common share – basic and diluted	\$ (0.09)	\$ -
Weighted average common shares outstanding - basic and diluted	57,628,502	40,736,035

**Deep Isolation Nuclear, Inc. and Subsidiaries**  
**Condensed Consolidated Statements of Changes in Stockholders' Equity**  
**(Unaudited) (in thousands, except share and per share data)**

	Common Stock		Preferred Stock Series A		Preferred Stock Series A Prime		Additional Paid in Capital	Accumulated Deficit	Accumulated Other Comprehensive	Total Stockholders' Equity
	Shares	Amount	Shares	Amount	Shares	Amount				
Balance, January 1, 2025	773,941	\$ -	655,351	\$ -	115,057	\$ -	\$ 29,962	\$ (27,167)	\$ 122	\$ 2,917
Retroactive application of Merger	39,127,838	4	(655,351)	-	(115,057)	-	(4)	-	-	-
Adjusted Balance beginning of quarter	<u>39,901,779</u>	<u>\$ 4</u>	<u>-</u>	<u>\$ -</u>	<u>-</u>	<u>\$ -</u>	<u>\$ 29,958</u>	<u>\$ (27,167)</u>	<u>\$ 122</u>	<u>\$ 2,917</u>
Exercise of stock options	1,330,620	-	-	-	-	-	70	-	-	70
Stock based compensation	-	-	-	-	-	-	25	-	-	25
Foreign currency translation adjustments	-	-	-	-	-	-	-	-	(49)	(49)
Net loss	-	-	-	-	-	-	-	(166)	-	(166)
<b>Balance, March 31, 2025</b>	<u><u>41,232,399</u></u>	<u><u>\$ 4</u></u>	<u><u>-</u></u>	<u><u>\$ -</u></u>	<u><u>-</u></u>	<u><u>\$ -</u></u>	<u><u>\$ 30,053</u></u>	<u><u>\$ (27,333)</u></u>	<u><u>\$ 73</u></u>	<u><u>\$ 2,796</u></u>
<b>Balance, January 1, 2026</b>	<u><u>57,542,113</u></u>	<u><u>\$ 6</u></u>	<u><u>-</u></u>	<u><u>\$ -</u></u>	<u><u>-</u></u>	<u><u>\$ -</u></u>	<u><u>\$ 59,456</u></u>	<u><u>\$ (32,503)</u></u>	<u><u>\$ 237</u></u>	<u><u>\$ 27,196</u></u>
Exercise of stock options and distribution of restricted stock units	105,500	-	-	-	-	-	4	-	-	4
Stock based compensation	-	-	-	-	-	-	522	-	-	522
Foreign currency translation adjustments	-	-	-	-	-	-	-	-	48	48
Net loss	-	-	-	-	-	-	-	(5,416)	-	(5,416)
<b>Balance, March 31, 2026</b>	<u><u>57,647,613</u></u>	<u><u>\$ 6</u></u>	<u><u>-</u></u>	<u><u>\$ -</u></u>	<u><u>-</u></u>	<u><u>\$ -</u></u>	<u><u>\$ 59,982</u></u>	<u><u>\$ (37,919)</u></u>	<u><u>\$ 285</u></u>	<u><u>\$ 22,354</u></u>

**Deep Isolation Nuclear, Inc. and Subsidiaries**  
**Condensed Consolidated Statements of Cash Flows**  
(Unaudited) (in thousands, except share and per share data)

	Three Months Ended March 31,	
	2026	2025
<b>Cash Flows from Operating Activities:</b>		
Net loss	\$ (5,416)	\$ (166)
Adjustments to reconcile net loss to net cash used in operating activities:		
Depreciation and amortization expense	25	29
Interest expense	1	-
Stock based compensation	522	25
Changes in operating assets and liabilities:		
Accounts receivable	(156)	174
Allowance for credit losses	2	8
Contract assets	(339)	10
Other current assets	50	17
Other non current assets	54	-
Account payable	126	55
Contract liabilities	(75)	-
Accrued expenses	(445)	(110)
Other current liabilities	407	(31)
Operating lease right-of-use assets and lease liabilities	2	1
<b>Net cash (used in) provided by operating activities</b>	<b>(5,242)</b>	<b>12</b>
<b>Cash Flows from Investing Activities:</b>		
Purchases of property, plant and equipment	(17)	(31)
<b>Net cash used in investing activities</b>	<b>(17)</b>	<b>(31)</b>
<b>Cash Flows from Financing Activities:</b>		
Payment of finance lease liability	(1)	(1)
Proceeds from exercise of stock options	4	70
<b>Net cash provided by financing activities</b>	<b>3</b>	<b>69</b>
<b>Net change in cash and cash equivalents</b>	<b>(5,256)</b>	<b>50</b>
Effect of exchange rate on cash and cash equivalents	48	(50)
<b>Cash and cash equivalents:</b>		
Beginning of period	27,434	2,149
End of period	<b>\$ 22,226</b>	<b>\$ 2,149</b>

**Supplemental schedule of non-cash investing and financing activities:**